RBC Capital analyst Arun Viswanathan lowered the firm’s price target on Chemours to $28 from $35 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results for Commodity Chemicals names. Earnings expectations in the second half of 2024 have come down further due to ongoing Europe weakness and unplanned outages throughout the quarter, and while construction demand should improve on interest rate cuts, the benefits are not likely to occur until mid-2025, the analyst tells investors in a research note. For Chemours, higher raw material costs and slow demand in Europe/Asia remain near-term headwinds, but the company’s titanium dioxide margins should recover in 2024, the firm added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on CC:

• Chemours price target raised to $32 from $30 at BMO Capital

• Chemours price target lowered to $21 from $22 at Barclays

• Woodward names Ron Charles as Chief Human Resources Officer

• Woodward names Ron Charles as Chief Human Resources Officer Chemours

• Chemours announces development of low GWP retrofit approach for vehicles